Ensuring product safety, consistency and full compliance with global regulatory standards.
IND Registration
Inspections
Founded in 2012, EirGenix Inc. specializes in the development of biopharmaceuticals and provides CDMO services.
The company operates two cGMP-compliant manufacturing facilities that meet international standards, offering end-to-end solutions from cell line development to commercial-scale production.
12.21
Eirgenix was established on December 21, 2012
Eirgenix was established on December 21, 2012
liter
12 x 2,000 liter single use bioreactors
12 x 2,000 liter single use bioreactors
LITER
microbial cGMP production (E. coli & Pichia systems)
microbial cGMP production (E. coli & Pichia systems)
EirGenix Inc. focuses on the development of biologics, including monoclonal antibodies and antibody-drug conjugates (ADCs), supported by a fully integrated R&D and GMP manufacturing platform.
EirGenix’s product and pipeline activities are focused on selected biologics programs, which have strengthened the company’s expertise in CMC development, process optimization, and regulatory compliance.
Driving sustainability through renewable energy, circular water use, and ISO-certified environmental systems.
EirGenix integrates ESG principles into every aspect of its operations.
Driving sustainability through renewable energy, circular water use, and ISO-certified environmental systems.
EirGenix integrates ESG principles into every aspect of its operations.
A comprehensive environmental management system is in place, ensuring compliance with international environmental standards.
RO-treated process wastewater is reused in cooling towers, enabling effective water resource recycling.
The share of green energy increased from 12.7% to 16.8% through solar power generation and green electricity procurement.